Reports And Data
Ulcerative Colitis Drug Market Size is Expected to Reach USD 7,511.3 Million in 2020, Growth at a CAGR of 4.50% by 2028
NEW YORK CITY, NEW YORK, UNITED STATES, July 14, 2022 /EINPresswire.com/ -- The global ulcerative colitis drug market is forecast to reach USD 10.69 Billion by 2028, according to a new report by Reports and Data. Ulcerative colitis (UC) can be defined as an inflammatory bowel disease, which is chronic in nature. Some of the mentionable symptoms associated with the condition is inflammation, irritation, and ulcers in the lining of the colon. The disease does not have a cure, and patients of the condition experience revival of the symptoms. However, with the help of the right treatment, the condition and associated signs & symptoms can be effectively managed. The exact cause for the occurrence of the condition remains unknown. Previously stress and diet was suspected to be the cause for the occurrence of the disease. However, now it is known that stress and diet may aggravate the condition.
Heredity and immune system malfunction are considered to be the possible cause for the occurrence of the disease. There are two main goals of UC treatment. The first is to control the symptom & enhance the comfort of patients and increasing the healing of colon. The second aim is to avoid more flare-ups. The focus of the treatment is to minimize & control the signs and symptoms of the disease. There are different types of drugs that may be prescribed by a doctor like Antibiotics, Corticosteroids, and Biologics, among others. In regards to region, Europe can be seen to occupy a prominent market share. The market share held by this region is the result of the high prevalence rate of the condition in this region, along with continuously expanding healthcare sector.
Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/2379
Top Key Players: Bausch Health Companies Inc. (Salix Pharmaceutical), AbbVie Inc., Johnson and Johnson, Boehringer Ingelheim GmbH, Novartis AG, Merck & Co., Teva Pharmaceuticals Ltd., Takeda Pharmaceuticals, Shire, Pfizer Inc.
Further key findings from the report suggest
The Ulcerative Colitis Drug market held a market share of USD 6.79 Billion in the year 2018 that is forecasted to grow at a rate of 4.6% during the forecast period.
In context to Drug Type, the Biologics segment generated the highest revenue of USD 2.78 Billion in 2018, with a CAGR of 4.50% during the forecast period. The effectiveness of Biologics in working in a selective manner, rather than affecting the whole body that results in reducing medication-related side effects and elevated preference among care providers and care users contributes to the revenue generated by this segment.
In context to Route of Administration, the Oral segment is projected to witness a faster growth rate of 5.4% during the forecast period. The growth rate witnessed by the segment is attributed to the presence of strong pipeline products and continuous developments in various drugs, along with rising awareness about the condition. Increasing awareness about the disease results in early detection of the condition and increasing demand for 5-aminosalicylic acid, which is usually the first step of treatment.
In context to Distribution Channel, the Hospitals Pharmacy segment held the largest market share of 45.0% in 2018, with a CAGR of 4.7% during the forecast period. The market share occupied by the Hospitals Pharmacy segment is resultant of the rising incidence rate of the condition, increase in the number of in-patient and out-patients, elevation in the number of hospitalization associated with the disease, which results in high demand for medications of the disease from this distribution channel.
In regards to Application, the Ulcerative proctitis segment generated the highest revenue of USD 3.80 Billion in 2018, with a CAGR of 5.1% during the forecast period. The high incidence rate of the condition results in high demand for UC drug in this segment.
Gain a better understanding of what more we have to offer:- https://www.reportsanddata.com/download-summary-form/2379
Segments covered in the report:
Drug Type Outlook (Revenue, USD Billion; 2018-2028)
Biologics
Corticosteroids
Immunomodulators
5-aminosalicylic acid
Immunosuppressant
Biosimilars
Others
Route of Administration Outlook (Revenue, USD Billion; 2018-2028)
Oral
Injectable
Distribution Channel Outlook (Revenue, USD Billion; 2018-2028)
Hospitals Pharmacy
Online Pharmacy
Retail Pharmacy
Application Outlook (Revenue, USD Billion; 2018-2028)
Proctosigmoiditis
Ulcerative proctitis
Pancolitis
Left-sided colitis
Acute severe ulcerative colitis
To know more about the report: https://www.reportsanddata.com/report-detail/ulcerative-colitis-drug-market
Regional Outlook (Revenue, USD Billion; 2018-2028)
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Tushar Rajput
Reports and Data
+ 12127101370
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
